PIEZO1 and neoplasm: Further statistical analysis showed that 80% (97/122) of ESCC patients' tumor tissues overexpressed PIEZO1, about 50% (57/122) of ESCC patients had a negative or weak expression of PIEZO1 in paracancerous normal tissue but the high expression in tumor tissue, indicating a considerable proportion of patients suitable for PIEZO1 antibody‐conjugate drugs (Figure 2A).